Hospital
Marion General Hospital
Marion General Hospital was paid $29.29M by Medicaid between Jan 2018 and Dec 2024, across 181 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoMARION GENERAL HOSPITAL
MARION, IN 46952
MARION, IN 46952
33aNPI1770679201assigned 10/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.29M
24GClaims867,472
24DCodes billed181
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#13 of 69
Median peer was paid$9.76M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 124,331 | $1.87M | |
| 2019 | 115,653 | $3.04M | |
| 2020 | 108,494 | $3.26M | |
| 2021 | 138,220 | $5.08M | |
| 2022 | 149,776 | $5.46M | |
| 2023 | 131,454 | $5.83M | |
| 2024incomplete | 99,544 | $4.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 50,563 | 45,248 | $6.87M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 41,500 | 35,585 | $5.83M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 17,739 | 14,188 | $2.06M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.5% | 31,671 | 23,373 | $1.61M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 10,326 | 9,498 | $1.29M |
| 71045 | Radiologic examination, chest; single view | 3.9% | 10,750 | 8,786 | $1.14M |
| 71046 | Radiologic examination, chest; 2 views | 3.3% | 8,924 | 7,761 | $960K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 2,658 | 2,300 | $727K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.2% | 448 | 390 | $633K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.1% | 1,093 | 420 | $628K |
| 99234 | 2.0% | 1,594 | 677 | $581K | |
| 80050 | General health panel | 2.0% | 3,399 | 3,161 | $574K |
169 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 4,738 | $474K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 10,238 | $472K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 2,730 | $381K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 104,795 | $381K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 5,308 | $352K |
| 80053 | Comprehensive metabolic panel | 1.2% | 77,043 | $345K |
| 36415 | Collection of venous blood by venipuncture | <1% | 156,259 | $267K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,770 | $248K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,768 | $248K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,734 | $200K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,386 | $191K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,030 | $179K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 454 | $173K |
| 84484 | <1% | 24,429 | $138K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,776 | $128K |
| 80061 | Lipid panel | <1% | 17,905 | $122K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,223 | $116K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 500 | $110K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,097 | $108K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,608 | $95K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,707 | $82K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 479 | $74K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,080 | $63K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,494 | $62K |
| 83735 | <1% | 16,647 | $55K | |
| 81025 | <1% | 11,527 | $54K | |
| 86780 | <1% | 4,865 | $52K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 557 | $52K |
| 87428 | <1% | 1,723 | $49K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,663 | $47K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 731 | $45K |
| 83690 | <1% | 15,136 | $42K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,911 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,858 | $39K |
| 96367 | <1% | 1,254 | $38K | |
| 84439 | <1% | 7,189 | $38K | |
| 99235 | <1% | 65 | $35K | |
| 81001 | <1% | 21,836 | $32K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 295 | $31K |
| 83880 | <1% | 1,968 | $31K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 42 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,721 | $28K |
| 86803 | <1% | 2,329 | $27K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 15 | $26K |
| 59025 | Fetal non-stress test | <1% | 65 | $24K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 353 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 879 | $22K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 988 | $20K |
| 82728 | <1% | 4,030 | $19K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 814 | $18K |
| 87340 | <1% | 2,351 | $17K | |
| 86706 | <1% | 1,852 | $17K | |
| 88142 | <1% | 1,208 | $16K | |
| 85610 | <1% | 9,071 | $16K | |
| 82077 | <1% | 1,916 | $16K | |
| 86705 | <1% | 1,474 | $15K | |
| 83605 | <1% | 3,265 | $15K | |
| 85730 | <1% | 5,532 | $15K | |
| 87631 | <1% | 253 | $14K | |
| 81003 | <1% | 12,042 | $13K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 623 | $13K |
| 87653 | <1% | 395 | $13K | |
| 84481 | <1% | 1,177 | $12K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 136 | $12K |
| 83550 | <1% | 4,028 | $12K | |
| 80076 | <1% | 2,942 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 58 | $12K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 926 | $12K |
| 86762 | <1% | 974 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,545 | $11K |
| 82607 | <1% | 1,257 | $10K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 365 | $10K |
| 76830 | Ultrasound, transvaginal | <1% | 42 | $9K |
| 83540 | <1% | 4,254 | $9K | |
| 86704 | <1% | 829 | $8K | |
| 85379 | <1% | 1,326 | $7K | |
| 84445 | <1% | 209 | $7K | |
| 80143 | <1% | 769 | $7K | |
| 80179 | <1% | 718 | $6K | |
| 86850 | <1% | 1,340 | $6K | |
| 87641 | <1% | 171 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 26 | $5K |
| 74174 | <1% | 13 | $5K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 36 | $4K |
| 86300 | <1% | 489 | $4K | |
| 86703 | <1% | 448 | $4K | |
| 83655 | <1% | 327 | $4K | |
| 84702 | <1% | 410 | $4K | |
| 83615 | <1% | 1,386 | $4K | |
| 73630 | <1% | 100 | $4K | |
| 82670 | <1% | 194 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 70 | $3K |
| 86140 | <1% | 1,348 | $3K | |
| 84482 | <1% | 317 | $3K | |
| 82962 | <1% | 1,811 | $3K | |
| 82550 | <1% | 1,404 | $3K | |
| 86900 | <1% | 1,138 | $3K | |
| 86901 | <1% | 1,151 | $3K | |
| 83001 | <1% | 209 | $3K | |
| 87905 | <1% | 239 | $2K | |
| 84144 | <1% | 179 | $2K | |
| 86376 | <1% | 248 | $2K | |
| 83002 | <1% | 193 | $2K | |
| 87081 | <1% | 356 | $2K | |
| 86800 | <1% | 219 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 97 | $2K |
| 82746 | <1% | 215 | $2K | |
| 82043 | <1% | 779 | $2K | |
| 82150 | <1% | 738 | $2K | |
| 84403 | <1% | 159 | $2K | |
| 82950 | <1% | 428 | $2K | |
| 87040 | <1% | 535 | $2K | |
| 87430 | <1% | 436 | $2K | |
| 85027 | <1% | 534 | $1K | |
| G0378 | Hospital observation service, per hour | <1% | 18 | $1K |
| 82570 | <1% | 411 | $1K | |
| 96523 | <1% | 18 | $1K | |
| 87186 | <1% | 360 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 63 | $965.82 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 46 | $923.72 |
| 84238 | <1% | 40 | $846.04 | |
| 87088 | <1% | 311 | $809.04 | |
| 87220 | <1% | 216 | $789.28 | |
| 87481 | <1% | 19 | $784.10 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 19 | $784.10 |
| 84480 | <1% | 102 | $767.29 | |
| 73610 | <1% | 48 | $724.96 | |
| 87205 | <1% | 172 | $653.83 | |
| 84145 | <1% | 218 | $646.32 | |
| 73130 | <1% | 75 | $600.46 | |
| 80074 | <1% | 12 | $571.56 | |
| 87512 | <1% | 19 | $555.00 | |
| 85652 | <1% | 403 | $503.68 | |
| 87799 | <1% | 19 | $440.51 | |
| 36416 | <1% | 282 | $382.50 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 63 | $344.15 |
| 73562 | <1% | 12 | $335.16 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 32 | $322.93 |
| 82784 | <1% | 18 | $316.20 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 14 | $229.66 |
| 83789 | <1% | 15 | $216.99 | |
| 84165 | <1% | 104 | $213.12 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 28 | $204.88 |
| 0352U | <1% | 306 | $199.52 | |
| 84146 | <1% | 36 | $187.92 | |
| 88304 | <1% | 37 | $178.69 | |
| 82565 | <1% | 48 | $168.72 | |
| 84460 | <1% | 45 | $158.29 | |
| 82803 | <1% | 28 | $137.04 | |
| 84703 | <1% | 13 | $97.76 | |
| 82378 | <1% | 16 | $94.80 | |
| 84155 | <1% | 172 | $88.78 | |
| 80069 | <1% | 30 | $86.80 | |
| 36600 | <1% | 26 | $68.80 | |
| 87070 | <1% | 41 | $42.58 | |
| 87077 | <1% | 16 | $38.68 | |
| 85045 | <1% | 17 | $9.56 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 56 | $0.00 |
| C9046 | Cocaine hydrochloride nasal solution (goprelto), 1 mg | 0% | 57 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 139 | $0.00 |
| 97802 | 0% | 30 | $0.00 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 16 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 50 | $0.00 |
| 0077U | 0% | 67 | $0.00 | |
| 94729 | 0% | 39 | $0.00 | |
| 88313 | 0% | 34 | $0.00 | |
| 94726 | 0% | 13 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialUSHER, PAUL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Marion General Hospital | Marion, IN | $2.01M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.